Urology PracticeChangers in 2015: A New Standard of Care for Early Metastatic Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Sweeney CJ, Chen Y, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-746.
- James ND, Sydes MR, Mason MD, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). Paper presented at: 2015 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2015; Chicago, IL. Abstract 5001. J Clin Oncol 33, 2015 (suppl; abstr 5001).
Disclosure statements are available on the authors' profiles: